Evidence map›Paper›PMID 34052323›Full record

ArticleCancer letters2021

Mixed Lineage Kinase 3 phosphorylates prolyl-isomerase PIN1 and potentiates GLI1 signaling in pancreatic cancer development.

Navin Viswakarma, Gautam Sondarva, Daniel R Principe, Rakesh Sathish Nair, Sandeep Kumar, Sunil Kumar Singh, Subhasis Das, Subhash C Sinha, Paul J Grippo, Sam Grimaldo and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Navin ViswakarmaDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Gautam SondarvaDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Daniel R PrincipeDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Rakesh Sathish NairDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Sandeep KumarDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Sunil Kumar SinghDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Subhasis DasDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Subhash C SinhaWeill Cornell Medicine, New York, NY, 10021, USA.
Paul J GrippoDepartment of Medicine, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Sam GrimaldoDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA.
Pier Cristoforo GiulianottiDivision of General, Minimally Invasive, and Robotic Surgery, The University of Illinois at Chicago, Chicago, IL, USA.
Basabi RanaDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA; University of Illinois Hospital & Health Sciences System Cancer Center, The University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown VA Medical Center, Chicago, IL, 60612, USA.
Ajay RanaDepartment of Surgery, Division of Surgical Oncology, The University of Illinois at Chicago, Chicago, IL, 60612, USA; University of Illinois Hospital & Health Sciences System Cancer Center, The University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown VA Medical Center, Chicago, IL, 60612, USA. Electronic address: arana@uic.edu.
University of Illinois Chicago · USCornell University · US

Funding

Developing Nano Technology for HER2 Directed TherapyR01CA216410 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LI, SONG, RANA, AJAY NMN · 2017 to 2021
$2.8M
Oncogenic MLK3-Pak1 Signaling in ER Negative Breast CancerR01CA176846 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, AJAY NMN · 2013 to 2017
$1.6M
Role of beta-catenin in apoptosis resistance of hepatocellular carcinomaR01CA178063 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, BASABI · 2014 to 2018
$1.6M
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway InhibitionF30CA236031 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRINCIPE, DANIEL R · 2019 to 2023
$256k
Mechanistic Insight on the Role of Berberine and AMPK in Hepatocellular CarcinomaR03CA219764 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, BASABI · 2019 to 2020
$160k
BLR&D Research Career Scientist Award ApplicationIK6BX004855 · VA · JESSE BROWN VA MEDICAL CENTER · PI AJAY NMN RANA · 2020 to 2026
–
Rational Combination of MAP4K4 Inhibition and Immunotherapy in Pancreatic CancerI01BX004903 · VA · JESSE BROWN VA MEDICAL CENTER · PI AJAY NMN RANA · 2021 to 2026
–
Elucidation of MLK3 Signaling in Hepatocellular CarcinomaI01BX003296 · VA · JESSE BROWN VA MEDICAL CENTER · PI RANA, BASABI · 2016 to 2022
–
Targeting Mixed Lineage Kinase3-Hedgehog Axis in Pancreatic CancerI01BX002703 · VA · JESSE BROWN VA MEDICAL CENTER · PI RANA, AJAY NMN · 2015 to 2019
–
BLRD VA I01 BX002703BLRD VA I01 BX003296BLRD VA I01 BX004903BLRD VA IK6 BX004855NCI NIH HHS F30 CA236031NCI NIH HHS R01 CA176846NCI NIH HHS R01 CA178063NCI NIH HHS R01 CA216410NCI NIH HHS R03 CA219764
6 · The paper itself

Abstract

The transcription factor Glioma-Associated Oncogene Homolog 1 (GLI1) is activated by sonic hedgehog (SHH) cascade and is an established driver of pancreatic ductal adenocarcinoma (PDAC). However, therapies targeting upstream hedgehog signaling have shown little to no efficacy in clinical trials. Here, we identify Mixed Lineage Kinase 3 (MLK3) as a druggable regulator of oncogenic GLI1. Earlier, we reported that MLK3 phosphorylated a peptidyl-prolyl isomerase PIN1 on the S138 site, and the PIN1-pS138 translocated to the nucleus. In this report, we identify GLI1 as one of the targets of PIN1-pS138 and demonstrate that PIN1-pS138 is upregulated in human PDAC and strongly associates with the upregulation of GLI1 and MLK3 expression. Moreover, we also identified two new phosphorylation sites on GLI1, T394, and S1089, which are directly phosphorylated by MLK3 to promote GLI1 nuclear translocation, transcriptional activity, and cell proliferation. Additionally, pharmacological inhibition of MLK3 by CEP-1347 promoted apoptosis in PDAC cell lines, reduced tumor burden, extended survival, and reduced GLI1 expression in the Pdx1-Cre x LSL-KRAS

Indexed as

AnimalsApoptosisCell Line, TumorCell ProliferationDisease Models, AnimalHumansMAP Kinase Kinase KinasesMiceMitogen-Activated Protein Kinase Kinase Kinase 11NIMA-Interacting Peptidylprolyl IsomerasePancreatic NeoplasmsPhosphorylationSignal TransductionTranscription, GeneticZinc Finger Protein GLI1GLI1 protein, humanMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11NIMA-Interacting Peptidylprolyl IsomerasePIN1 protein, humanZinc Finger Protein GLI1Cell biologyGLI1MLK3OncogenesPancreatic cancerPIN1

Identifiers

PMID34052323
PMCPMC8215900
OpenAlexW3165886086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.